Cell: Mouse SARS-CoV-2 Infection Model Reveals Protective Effects of Neutralizing Antibodies

, June 2020 /
BiovalleyBIOON /- Severe Acute Respiratory Syndrome 2 coronavirus (SARS-CoV-2) has caused a pandemic in millions of peopleOne limitation in evaluating potential therapies and vaccines to suppress SARS-CoV-2 infection and improve the disease is the lack of a large number of susceptible small animal modelsCommercially available laboratory mice were less susceptible to SARS-CoV-2 because of species-specific differences in their angiotensin-enzyme 2 (angiotensin-enzymeing 2, ACE2) receptorsdeveloped a new model of SARS-CoV-2 infection in mice based on SARS-CoV-2, published recently in the journal Cell, in the journal Cell, led by Michael SDiamond, a professor in the Department of Medicine, Pathology andImmunology,
and The Department of Molecular Microbiology, michael SDiamond, from the University of Washington School of Medicine in StLouisPhoto Source: Cell
Highlights of the study are:adenovirus transduction ACE2 makes it possible for BALB/c mice to become infected with SARS-CoV-2;mice with high levels of viral RNA and infectious SARS-CoV-2 virus;human ACE2-transified mice with viral pneumonia after contracting SARS-CoV-2; and monoclonal antibodies incan prevent SARS-CoV-2 inthem In this study, the researchers successfully transmitted the replication defect adenovirus encoded in human ACE2 (hACE2) to BALB/c mice through nasal administration, successfully expressing hACE2 receptors in the lung tissue of mice , the researchers then infected the mice with SARS-CoV-2 viruses It was shown that the mice transinated by hACE2 were effectively infected by SARS-CoV-2, which led to high viral titer in lung tissue, lung pathology characteristics of new coronary pneumonia in mice, and weight loss to reveal the therapeutic effects of neutralizing antibodies, the researchers treated the mice with neutral monoclonal antibodies The researchers found that neutralizing antibody therapy reduced the burden of the virus on the lungs, reducing inflammation and weight loss symptoms researchers say the development of a model of SARS-CoV-2 infection and pathogenesis in available mice will speed up the testing and deployment of therapeutic drugs and vaccines (BioValleyBioon.com) References: Michael S Diamond et al.
, A SARS-CoV-2 infection model in mice shofs protection by neutralizing antibodies Cell 2020 DOI: https://doi.org/10.1016/j.cell.2020.06.011